End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
41.96 CNY | -1.57% | +1.87% | -42.33% |
Apr. 17 | Interest Rate Outlooks Quell Asian Stock Markets | MT |
Apr. 11 | Western Drugmakers Seeking Alternative Suppliers as US Looks to Restrict Chinese Biotech | MT |
Business Summary
- laboratory services (60.9%): small molecules discovery services, bioanalytical services, medical devices safety testing services, comprehensive manufacturing and testing services for cell and gene therapies, etc.;
- CMO and CDMO services (31.9%): development of manufacturing processes, production of advanced intermediates and active pharmaceutical ingredients, formulation development and dosage drug product manufacturing, for preclinical and clinical trials, new drug application, and commercial supply of chemical drugs, etc.;
- clinical research services (7.1%): project planning, clinical operation and monitoring and managements of phase I-IV clinical trials, medical device trials, etc.;
- other (0.1%).
Net sales are distributed geographically as follows: China (25.1%), Asia (4.1%), the United States (53.6%), Europe (16%) and other (1.2%) .
Number of employees: 41,116
Sales per Business
CNY in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Chemical
72.3
%
| 28,850 | 73.3 % | 29,171 | 72.3 % | +1.12% |
Test
16.2
%
| 5,719 | 14.5 % | 6,540 | 16.2 % | +14.36% |
Biology
6.3
%
| 2,475 | 6.3 % | 2,553 | 6.3 % | +3.13% |
High-end treatment CTDMO
3.2
%
| 1,308 | 3.3 % | 1,310 | 3.2 % | +0.12% |
Domestic New Drug Research and Development Service
1.8
%
| 970 | 2.5 % | 726 | 1.8 % | -25.08% |
Other Business
0.1
%
| 34 | 0.1 % | 41 | 0.1 % | +22.12% |
Sales per region
CNY in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
64.8
%
| 25,884 | 65.8 % | 26,132 | 64.8 % | +0.96% |
China
18.3
%
| 7,526 | 19.1 % | 7,372 | 18.3 % | -2.05% |
Europe
11.6
%
| 4,432 | 11.3 % | 4,698 | 11.6 % | +6.00% |
Other Regions
5.3
%
| 1,512 | 3.8 % | 2,139 | 5.3 % | +41.46% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Zhao Hui Zhang
FOU | Founder | 54 | 00-11-30 |
Ge Li
CEO | Chief Executive Officer | 56 | 00-11-30 |
Qing Yang
CEO | Chief Executive Officer | 55 | 15-11-30 |
Min Zhang Chen
CEO | Chief Executive Officer | 54 | - |
Florence Shi
DFI | Director of Finance/CFO | 50 | 21-12-31 |
Ellis Chu
DFI | Director of Finance/CFO | - | - |
Ming Shi
DFI | Director of Finance/CFO | 49 | 21-03-31 |
Edward Hu
CIO | Chief Investment Officer | 61 | 06-12-31 |
Guo Dong Tong
COO | Chief Operating Officer | - | - |
Chief Tech/Sci/R&D Officer | - | 19-04-07 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Edward Hu
CIO | Chief Investment Officer | 61 | 06-12-31 |
Xiao Meng Tong
BRD | Director/Board Member | 50 | 16-03-22 |
Ge Li
CEO | Chief Executive Officer | 56 | 00-11-30 |
Zhao Hui Zhang
FOU | Founder | 54 | 00-11-30 |
Shao Hua Lu-Wong
BRD | Director/Board Member | 55 | 23-05-30 |
Yi Bing Wu
BRD | Director/Board Member | 55 | 16-03-22 |
Min Zhang Chen
CEO | Chief Executive Officer | 54 | - |
Qing Yang
CEO | Chief Executive Officer | 55 | 15-11-30 |
Bo Yang Wu
BRD | Director/Board Member | 60 | 99-12-31 |
Wei Yu
BRD | Director/Board Member | 71 | 23-05-30 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 387,076,150 | 0 | 0 | 66.64 % |
Stock B | 1 | 2,546,260,847 | 1,954,766,391 ( 76.77 %) | 0 |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
WUXI XDC CAYMAN INC. 50.10% | 600,000,000 | 50.10% | 1,402,932,000 $ |
LYELL IMMUNOPHARMA, INC. 3.22% | 8,180,678 | 3.22% | 18,242,912 $ |
ADAGENE INC. 9.65% | 4,225,696 | 9.65% | 11,831,949 $ |
SENSORION 1.90% | 5,249,608 | 1.90% | 4,359,904 $ |
CASTLE BIOSCIENCES, INC. 0.02% | 6,636 | 0.02% | 146,987 $ |
PURPLE BIOTECH LTD 0.75% | 194,139 | 0.75% | 130,073 $ |
Company contact information
WuXi AppTec Co., Ltd.
288 Fute Middle Road Waigaoqiao Free Trade Zone
200131, Shanghai
+86 21 5046 1111
http://www.wuxiapptec.com.cnGroup companies
Name | Category and Sector |
---|---|
STA Pharmaceutical Hong Kong Ltd.
STA Pharmaceutical Hong Kong Ltd. Pharmaceuticals: MajorHealth Technology Part of New Wuxi Life Science Holdings Ltd., STA Pharmaceutical Hong Kong Ltd. is a pharmaceutical manufacturing company. The private company is based in Hong Kong, Hong Kong. |
Pharmaceuticals: Major
|
Sector
Sales per Business
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-42.33% | 16.6B | |
-1.51% | 105B | |
+3.22% | 97.5B | |
+1.86% | 22.19B | |
-16.53% | 21.33B | |
-8.49% | 18.68B | |
-20.09% | 14.52B | |
+5.47% | 14.09B | |
+28.85% | 10.99B | |
-24.93% | 8.63B |
- Stock Market
- Equities
- 603259 Stock
- Company WuXi AppTec Co., Ltd.